GAB1 and breast cancer: To validate our in silico identified hits, we performed three types of experimental assays to evaluate their bioactivities: direct binding to GAB1 PH domain, inhibition of Y627 phosphorylation of GAB1, and cytotoxicity IC50 in triple negative MDA-MB-231 and T47D human breast cancer cells.